Purpose of the Whitepaper
Our newly published whitepaper, “Integrated Evidence Generation: Ensuring Your Organization Has a Built-for-Purpose Evidence Engine“, aims to guide biopharmaceutical companies through the complexities of evidence-generation planning. The paper emphasizes the need for a strategic, proactive approach to evidence generation, which should begin early in an asset’s lifecycle. By adopting this approach, companies can better communicate the value of their therapies, thereby enhancing their chances of approval, clinical uptake and reimbursement.
Key Takeaways
This whitepaper identifies several critical elements for effective evidence generation, based on Prescient’s expertise in evidence-generation planning and interviews with industry experts, and aims to provide a how-to guide for readers to assess and improve their organization’s evidence-generation capabilities. The paper starts by underscoring the importance of cross-functional collaboration, which allows stakeholders from various departments to contribute their expertise throughout the evidence-generation process. Secondly, it recommends the establishment of a standardized operating model that includes clear roles, responsibilities and processes. This model should be flexible enough to adapt to feedback and the organization’s fluctuating needs. Lastly, the paper highlights the necessity of continuous assessment and adjustment of the operating model to ensure its effectiveness and alignment with organizational goals.
Case Study
Below is a case study showcasing how Prescient supported a mid-size oncology-focused pharmaceutical company in implementing a novel approach to improve strategic decision making in regard to evidence generation. The company faced challenges such as portfolio complexity, with multiple assets in overlapping disease areas, lack of clear governance and limited transparency across internal stakeholders, and therefore sought support to evaluate its capabilities and design and implement a bespoke evidence-generation strategy. This included the implementation of pilot programs, the establishment of necessary forums, guidance on ways of working, the outlining of clear governance structures and the standardization of planning processes. These changes led to significant improvements in evidence-generation planning, including increased transparency across asset teams and functions and faster and higher-quality decision making. Ultimately, the organization achieved greater autonomy and efficiency in strategic decision making, demonstrating the value of a robust evidence-generation strategy.
By implementing the insights and strategies outlined in our whitepaper, your organization can optimize its evidence-generation efforts, driving long-term value and success in a competitive biopharmaceutical landscape.
